Howard Hochster, MD, FACP

Howard S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers.

Howard S. Hochster, MD, discusses data from the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care in metastatic colorectal cancer.

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.

Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.

Howard Hochster, MD, FACP, discusses results from the SWOG S1513 study, which examined the use of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) versus solely FOLFIRI in metastatic pancreatic cancer.